Program
fexuprazan
Also written as “DWP14012”, “DWP14012 20mg” and “DWP14012 40mg”.
Its studies are mostly in Esophagitis · Gastroesophageal Reflux · Stomach Ulcer · Peptic Ulcer · Non-Erosive Reflux Disease, led by 2 companies.
Drug pageFexuprazan: every studyAll 33 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Daewoong Pharmaceuticalits history only | 285 open or running | phase 4since Apr 8, 2026 | Mar 16, 2016 | Dec 2027phase 4 · NCT07533266 |
| GlaxoSmithKline | 10 open or running | phase 1since Dec 15, 2011 | Dec 15, 2011 | none ahead |
Also a collaborator on its studies: Shanghai Haini Pharmaceutical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of GlaxoSmithKline only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 15, 2011First study: phase 1 study in Prostatic HyperplasiaFirst studyNCT01495026 · 63 enrolled · Australia
TargetBeta
“Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Esomeprazolerule | AstraZeneca | phase 4 | 129 |
| Rabeprazolerule | Eisai | phase 4 | 66 |
| Omeprazolerule | AstraZeneca | phase 4 | 56 |
| tegoprazanrule | HK inno.N | phase 4 | 48 |
| vonoprazanrule | Takeda | phase 4 | 48 |
Studies
The one study GlaxoSmithKline leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01495026Prostatic Hyperplasia · Australia | 1 | Completed | Apr 3, 2012 | 63 |
How it is read
Names in the registry
- “DWP14012”, 10 entries
- “DWP14012 20mg”, 3 entries
- “DWP14012 40mg”, 3 entries
- “DWP14012 tablet A”, 3 entries
- “DWP14012 tablet B”, 3 entries
Conditions, from the studies’ own filings
- Esophagitis, 4 studies
- Gastroesophageal Reflux, 3 studies
- Stomach Ulcer, 1 study
- Peptic Ulcer, 1 study
- Non-Erosive Reflux Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.